Compare Abeona Therapeutics Inc (ABEO) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs SMX Security Matters plc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while SMX Security Matters plc trades at $16.48 (market cap $17.04M). The key difference: Abeona Therapeutics Inc is far larger — about 24.7× SMX Security Matters plc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| ABEO | SMX | |
|---|---|---|
Market Cap | $421.19M | $17.04M |
Sector | Health | Technology |
52-Week High | $7.45 | $103.71K |
52-Week Low | $4.17 | $12.87 |
Enterprise Value | $276.10M | -$14.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
SMX trades at $16.45, up 4.11% today, amid a reverse stock split effective June 1, 2026. The stock shows bearish technical signals with support at $16 and resistance at $17. Financially, the company reported a net loss of $169.18 million for 2025, with negative ROE and ROA, though it strengthened its balance sheet with $77 million in financing in 2026. Recent news highlights SMX's focus on recycled plastic verification and commercialization strategies.
The outlook remains speculative; SMX's technology addresses growing demand for material traceability, but persistent losses and high cash burn pose significant risks. Investor sentiment is cautious due to weak profitability, though institutional financing provides near-term liquidity. The stock's viability hinges on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
